Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-dose fine particles vs low/medium-dose ultrafine particles ICS/LABA in mild-to-moderate asthma with poor response to low-dose budesonide/formoterol
ChiCTR2100045663Phase 4Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of beclomethasone, formoterol and budesonide in asthma (3 arms), sponsored by Shanghai General Hospital. Primary endpoint: Lung function. Started Apr 2021; status: recruiting.
02
Drugs
beclomethasoneformoterolbudesonide
03
Conditions
asthma
Beyond the preview
Go deeper on ChiCTR2100045663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045663.